Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations. BRCA1- and BRCA2-mutated cells, which are homologous recombination (HR) deficient, are hypersensitive to PARPi through the mechanism of...

Full description

Saved in:
Bibliographic Details
Published in:Nat Commun
Main Authors: Ding, Xia, Chaudhuri, Arnab Ray, Callen, Elsa, Pang, Yan, Biswas, Kajal, Klarmann, Kimberly D., Martin, Betty K., Burkett, Sandra, Cleveland, Linda, Stauffer, Stacey, Sullivan, Teresa, Dewan, Aashish, Marks, Hanna, Tubbs, Anthony T., Wong, Nancy, Buehler, Eugen, Akagi, Keiko, Martin, Scott E., Keller, Jonathan R., Nussenzweig, André, Sharan, Shyam K.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979061/
https://ncbi.nlm.nih.gov/pubmed/27498558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12425
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items